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medial elastin.4,5 In this regard, increased production of
several members of the matrix metalloproteinase (MMP)
family, including collagen-degrading proteinases such
as collagenase and gelatinase and elastin-degrading
proteinases such as macrophage elastase, have been
reported.6,7
Under healthy physiologic conditions, the amounts of
the different proteins of the extracellular matrix (ECM)
reach an equilibrium between synthesis and degradation.8
MMPs are expressed at low levels in healthy tissues but
play an important role in the remodeling of ECM in
numerous pathologic states, including AAAs.9 Regulation
of these MMPs occurs not only at the gene expression
level but also at a posttranslational level with enzymatic
activation of their proenzyme forms. Of those activators,
membrane-type 1 MMP (MT1-MMP), a membrane-
bound MMP, has been shown to play a crucial role in the
activation of the gelatinase MMP-2 at the cell surface.10,11
The catalytic activities of MMPs also are partly controlled
by specific inhibitors called tissue inhibitors of MMPs
(TIMPs).12 Among these, TIMP-3 specifically promoted
the apoptotic death of SMCs, which contributed to
reduced neointima formation in vitro and in vivo.13 Thus,
an altered balance between MMPs and TIMPs is thought
to result in the uncontrolled destruction of elastin and col-
lagen within the aortic wall and the promotion of the
development of AAAs.14
There is considerable interest in understanding the
cellular and biochemical mechanisms that underlie tissue
Abdominal aortic aneurysms (AAAs) represent a
potentially fatal disorder that is characterized by the
destruction of medial elastin, chronic aortic wall inflam-
mation, and the loss of smooth muscle cells (SMCs).
Factors such as aging, atherosclerosis, high blood pres-
sure, and cigarette smoking have been linked to the patho-
genesis of AAAs.1 However, the origin of AAA formation
still remains unclear because this degenerative vascular dis-
ease also includes a genetically inherited component.2
Tissue remodeling is a prominent characteristic associated
with the progressive degeneration of the aortic wall, the
structural integrity of which depends primarily on elastin
and collagen.3 Recent studies have emphasized the role of
elastolytic proteinases in the disruption and degradation of
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Background: The increased synthesis of matrix metalloproteinases (MMPs) by aortic smooth muscle cells (SMCs) is
thought to be involved in the etiopathogenesis of abdominal aortic aneurysms (AAAs), but the functional regulation
and the activation states of these MMPs remain unclear. In this study, we assessed the expression levels and the func-
tional regulation of several MMPs in the pathogenesis of AAAs.
Methods: Human healthy aorta and AAA specimens were homogenized, and the proteolytic activities of MMP-2 and
MMP-9 and of the macrophage metalloelastase (MMP-12) were assessed with zymography. Protein expression of
MMP-1, MMP-12, membrane-type 1 MMP (MT1-MMP), tissue inhibitor of MMP 1 (TIMP-1), TIMP-2, TIMP-3,
α-actin, and β-actin was analyzed with electrophoresis on sodium dodecyl sulfate gels and immunoblotting.
Results: MMP-1, MMP-9, and MMP-12 zymogen levels and proteolytic activities were increased in AAAs when com-
pared with healthy aorta. A severe reduction in α-actin–positive vascular SMCs was observed in all the AAA specimens
and was correlated with an increase in TIMP-3 but not TIMP-1 or TIMP-2 potential activities. Although pro–MMP-
2 activity was decreased, the extent of activated MMP-2 remained unaffected in the AAAs. In accordance with this
result, a highly activated MT1-MMP form was also observed in AAAs.
Conclusion: These data suggest that chronic aortic wall inflammation is mediated by macrophage infiltration, which
may account for the destruction of medial elastin, as reflected by SMC down regulation, through increased levels of
active MMP-1 and MMP-12. Moreover, altered MT1-MMP proteolytic turnover and differential regulation of TIMP
expression in AAAs suggest that tight regulatory mechanisms are involved in the molecular regulation of MMP activa-
tion processes in the pathogenesis of AAAs. (J Vasc Surg 2002;35:539-46.)
remodeling in aneurysms. Recent study results have
shown a pivotal role for some MMPs in AAA pathogene-
sis.15 For instance, the expressions of gelatinases MMP-2
and MMP-9 and of the macrophage metalloelastase
(MMP-12) have been reported to be stimulated at the
messenger RNA (mRNA) and protein levels in human
AAA tissue as compared with healthy aortas.4,15 The key
role of MMPs in AAA development is also strongly
supported with data that show that synthetic MMP
inhibitors16,17 and overexpressed recombinant TIMP-118
blocked aneurysm growth in a rat model. More recently,
targeted gene disruption of MMP-9 completely sup-
pressed the development of experimental AAAs.19
Several study results thus have documented increased
MMP mRNA levels in AAAs. Moreover, the balance
between MMPs and TIMPs also has generally been
assessed at the transcription level.7,14,20 Whether with
reverse transcription polymerase chain reaction or with
Northern blot test, the assessment of mRNA expression
remains mostly informative with regards to the regulation
of the genes that encode MMPs in AAAs. Furthermore, to
become fully active, soluble MMPs must be proteolyzed
because they are synthesized and secreted as zymogens.8
Thus, there is an indirect link between the gene expression
and the functional state of MMPs. Immunohistochemical
techniques used in the analysis of the expression of MMPs
at the protein level together with immunoassay allow the
localization or the quantification of MMPs. Unfortunately, in
some reports, the determination of whether the assayed
MMPs exist as inactive precursors or activated proteinases
is unclear or not possible. Thus, the functional regulation
of MMPs and TIMPs at the protein level and their contri-
bution to ECM proteolysis in AAA formation remain to
be clarified.
In this study, we first assessed the content of α-actin
and β-actin, two highly conserved proteins and major
components of both the cytoskeletal and contractile struc-
tures, in healthy aorta and aortic aneurysms as markers of
arterial wall deterioration. We then used immunoblotting
and zymographic techniques to directly measure expres-
sion and activity of both the latent (pro-MMP) and active
forms of MMPs, namely MMP-1, MMP-2, MMP-9, and
MT1-MMP, in human tissues derived from healthy aorta
and aortic aneurysms. The extent of macrophage infiltra-
tion also was assessed with the measurement of MMP-12
activity and protein expression. Finally, we characterized
the expression of three MMP inhibitors, TIMP-1, TIMP-
2, and TIMP-3, to provide a clearer understanding of the
role and balance between MMPs and their inhibitors in
aortic aneurysmal pathology.
MATERIALS AND METHODS
Antibodies and chemicals. The following materials
were purchased: rabbit polyclonal antibodies against
TIMP-3, MMP-1, and MT1-MMP and mouse mono-
clonal antibodies against TIMP-1 and TIMP-2 from
Chemicon International Inc (Temecula, Calif); mouse
monoclonal antibody against MMP-12 from R&D
Systems (Minneapolis, Minn); monoclonal antibodies
against α-actin and β-actin from Sigma (St Louis, Mo);
and donkey anti-rabbit and anti-mouse horseradish perox-
idase-conjugated antibodies and the enhanced chemilumi-
nescence detection system from Amersham (Oakville,
Ontario, Canada). Brij-35 was from Pierce (Rockford, Ill).
Triton X-100 was from BDH (Toronto, Ontario,
Canada). All the products for electrophoresis and zymog-
raphy were from Bio-Rad (Mississauga, Ontario, Canada).
Tissue specimens and preparation of artery
homogenates. The entire wall of aneurysmal aortic speci-
men was obtained from five patients (two men and three
women) aged 61 to 84 years (average age, 67.2 years) who
provided informed consent before AAA resection. The
specimens of healthy ascending thoracic aorta were
obtained from 16 patients (nine men and seven women)
aged 55 to 77 years (average age, 68.9 years) who under-
went coronary aortic bypass grafting. All the measure-
ments of aneurysmal lesions were estimated with
angiography before tissue analysis. Healthy aortic speci-
mens had diameters of 3 cm at the time of organ harvest,
and aortic aneurysm diameters ranged from 4.6 to 10.0
cm (average diameter, 6.7 cm). The aortic aneurysms were
subdivided for histology and biochemical studies. The tis-
sues were washed in sterile ice-cold 0.85% NaCl solution
to remove blood and serum contamination and then were
finely diced and weighed. The diced tissues then were
homogenized in 5 volumes of ice-cold 250 mmol/L
sucrose solution and 10 mmol/L N-2-hydroxyethylpiper-
azine-N-2-ethanesulfonic acid/tris pH 7.5 solution with a
Polytron (Brinkmann Instruments, Roxdale, Ontario,
Canada). Unbroken cells and nuclei were removed with
centrifugation at 3000 × g for 10 minutes at 4ºC as previ-
ously described.21 Protein concentration in supernatants
was measured with the method of Bradford (Pierce), with
bovine serum albumin as the standard. All tissue
homogenates were stored at –80ºC until use.
Zymography. Sodium dodecyl sulfate (SDS) poly-
acrylamide gel electrophoresis and zymography of pro-
teins were performed in a discontinuous system with a
Mini-Protean II apparatus (Bio-Rad). For the characteri-
zation of the metalloproteinases in different arteries, the
proteins were separated with nonreducing conditions on
7.5% or 12.5% polyacrylamide gels that contained 0.1%
(weight/volume [v]) gelatin (for MMP-2 and MMP-9
activities) or casein (for MMP-12 activity). After the
migration, the proteins were refolded in 2.5% Triton X-
100 to remove SDS, washed with distilled water, and incu-
bated in 50 mmol/L Tris-HCl pH 7.6, 20 mmol/L NaCl,
5 mmol/L CaCl2, and 0.02% (v/v) Brij-35 overnight at
37ºC to allow substrate cleavage with proteinases. The
gels then were stained with 0.1% Coomassie Brilliant blue
R-250 and destained in 10% acetic acid and 30% methanol
in H2O. Gelatinolytic activity was detected as unstained
bands on a blue background. All of the results are repre-
sentative of the two experiments done in duplicate.
Western blot analysis. For the immunoblotting
experiments, the proteins were electroblotted onto 0.45-
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µm pore diameter polyvinylidene difluoride membranes
(Immobilon-P, Millipore, Nepean, Ontario, Canada) in
transfer buffer (96 mmol/L glycine, 10 mmol/L Tris, 10%
methanol) at 80 mA per gel for 1 to 1.5 hours. The blots
were blocked overnight at 4°C in Tris-buffered saline solu-
tion (TBS; 137 mmol/L NaCl, 20 mmol/L Tris pH 7.5)
that contained 0.1% (v/v) Tween and 5% nonfat dried milk
(Carnation). The polyvinylidene difluoride membranes
then were incubated with a 1:500 dilution of MT1-MMP,
MMP-12, or β-actin antibodies, with a 1:1000 dilution of
MMP-1, TIMP-1, TIMP-2, or TIMP-3 antibodies, or
with a 1:2000 dilution of α-actin or β-actin antibodies in
TBS that contained 0.1% (v/v) Tween and 3% bovine
serum albumin for 1 hour at room temperature. The mem-
branes then were washed and incubated for 1 hour with
donkey anti-rabbit or anti-mouse immunoglobulin G con-
jugated to horseradish peroxidase in TBS with 0.1% (v/v)
Tween. Immunoreactive bands were detected with the
enhanced chemiluminescence Western blotting kit as
described in the manufacturer’s instructions (Amersham,
Montreal, Canada) with Fuji films and were quantified
with densitometric measurement with a Personal
Densitometer (Molecular Dynamics, Sunnyvale, Calif). All
of the results are representative of the two experiments
done in duplicate.
Statistical analysis. Statistical significance was assessed
with the Student t test. Values of less than .05 were con-
sidered significant, and such significance over values of
healthy aorta are identified in Figs 1 to 4.
RESULTS
Assessment of aortic wall integrity in abdominal
aortic aneurysms. AAAs are characterized by the struc-
tural deterioration of the aortic wall, which leads to pro-
gressive aortic dilatation and eventual rupture. These
histopathologic changes are attributed to the thinning of
the tunica media vasorum, which is normally dominated
by α-actin–positive vascular SMCs.22 In this study,
immunoblotting with specific antibodies permitted the
discrimination between the α-actin and β-actin isoforms
for the assessment of the structural integrity of the aortic
wall in AAAs (Fig 1,A). We observed that aneurysmal
aorta were characterized by a 90% decrease in the α-actin
protein level, a marker for SMCs, when compared with
healthy aorta (Fig 1,B). In contrast, β-actin, which is
expressed in most cell types, exhibited slightly reduced
expression (about 17%) in AAAs. These data show the
severe reduction in SMCs in all of the AAA specimens
used in this study.
Aortic structural deterioration accompanied by
increased expression and activation of pro–matrix met-
alloproteinase 1 in abdominal aortic aneurysms. The
remodeling of the aortic wall is prominently associated
with the progressive degeneration of the elastic media in
AAAs and is thought to be mediated by several
MMPs.23,24 For the further investigation of the role of
MMPs in medial degeneration in AAAs, we performed
Western blot test of MMP-1, which degrades different
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types of collagen, and found a striking increase in
pro–MMP-1 (approximately 8-fold that in healthy aorta)
in AAAs (Fig 2). In addition, the activation of pro–MMP-1
was also seen to be induced because the cleaved active
product of MMP-1 was immunodetected in three AAA
specimens as a 45-kd protein (Fig 2,A). Because high plas-
min levels have been reported in AAA tissues,25 the pres-
ence of this activated MMP-1 form may also reflect the
involvement of activation cascades involving plasmin. 
Macrophage metalloelastase expression and activ-
ity are greatly increased in abdominal aortic
aneurysms. Because MMP-12 is an elastin-degrading
proteinase with a predominantly macrophage-specific pat-
tern of expression, we investigated the MMP-12 expres-
sion and functional activity in AAAs. Human MMP-12 is
expressed as a proenzyme of 54 kd from which both the
propiece and C-terminal domains are removed during
processing, which leads to an active enzyme of 22 kd.
Accordingly, with our antibody, immunoblotting analysis
detected the pro–MMP-12 and an intermediate 48-kd
MMP-12 processed form (Fig 5,A), whereas the fully
active 22-kd MMP-12 form, which does not contain the
C-terminal hemopexin-like domain, remained unde-
tectable. In AAAs, the pro–MMP-12 protein level
increased about 9-fold of that in the healthy aorta (Fig
Fig 1. Expression of actin isoforms in aortic aneurysms. For
analysis of expression of α-actin and β-actin, abdominal aortic
aneurysms (AAAs; n = 4) and healthy aorta (n = 4) were homog-
enized. Proteins (25 mg/well) were resolved on 12.5% SDS-
polyacrylamide electrophoresis gel and (A) α-actin and β-actin
were immunodetected as described in Materials and Methods sec-
tion. B, Quantification of α-actin (healthy aorta, 100 ± 12, ver-
sus AAA, 15 ± 4) and β-actin (healthy aorta, 100 ± 3, versus AAA,
85 ± 2) levels was performed with densitometry and is expressed
as percent of values for healthy aorta.
*Values of less than .05 were considered significant.
NA, Healthy aorta.
A
B
5,A). The assessment of MMP-12 activity in AAAs was
then performed with casein zymography (Fig 5,B). As
expected, the overexpression of pro–MMP-12 in AAAs led
to increased caseinolytic MMP-12 activity. Such increased
activity was not observed in healthy aorta. 
Matrix metalloproteinases 2 and 9 gelatinolytic
activities are differentially regulated in artery
homogenates of abdominal aortic aneurysms. The cru-
cial role of MMPs in AAA pathogenesis prompted us to
perform gelatin substrate zymography to measure the
respective extent of proteolytic activities of the latent and
activated forms of MMP-2 and MMP-9 in healthy aorta
and AAAs. Both MMPs are known to degrade several
ECM proteins, including elastin, and are produced in vivo
as inactive proenzymes.26 Fig 6 shows that the gelati-
nolytic activities of the latent pro–MMP-9 (92 kd),
pro–MMP-2 (72 kd), and the activated form of MMP-2
(69 kd) were detected in both the healthy and aneurysmal
aorta. The expression patterns of these two gelatinases,
however, varied between the two types of arteries.
Pro–MMP-9, which may originate from infiltrating
macrophages and from SMCs, was the predominant
gelatinase expressed in AAAs. In contrast, healthy aorta
specimens presented a higher expression of pro–MMP-2
than did AAAs (Fig 6). These observations are consistent
with previously reported increases in MMP-9 mRNA
expression that correlated with increased aortic diameter
of AAAs27 and with increased MMP-9 activity in unstable
carotid plaques.28 Interestingly, our results also show that
total MMP-2 gelatinolytic activity is diminished in AAAs,
which may partially be reflected by the diminished level of
SMCs. Furthermore, we also observed that the level of
active MMP-2 form was of the same magnitude as that of
healthy aorta (Fig 6). These data indicate a distinct mod-
ulation of MMP-2 production in AAAs either with down
regulation of gene expression or with preferential activa-
tion of pro–MMP-2 mediated by MT1-MMP or TIMP-2.
These data prompted us to examine the activation state of
MT1-MMP, a cell-surface receptor and activator of
pro–MMP-2.10,29
Increased active membrane-type 1 matrix metallo-
proteinase protein levels are the result of altered pro-
teolytic turnover in abdominal aortic aneurysms.
Altered regulation of pro–MMP-2 was recently reported
for aortic SMCs.30 However, MT1-MMP expression and
activity patterns remain to be established in AAAs. MT1-
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Fig 2. Increased matrix metalloproteinase 1 (MMP-1) protein
expression in aortic aneurysms. Protein homogenates of healthy
aorta (n = 3) and abdominal aortic aneurysms (AAAs; n = 5) were
resolved (25 mg/well) on 9% SDS-polyacrylamide electrophore-
sis gel as described in Materials and Methods section. A,
Immunoblots of expression of active MMP-1 (45 kd) and
pro–MMP-1 (53 kd) forms are shown. B, Quantification of
pro–MMP-1 protein level (healthy aorta, 100 ± 22, versus AAA,
769 ± 25) was performed with densitometry and is expressed as
percent of values for healthy aorta.
*Values of less than .05 were considered significant.
NA, Healthy aorta.
Fig 3. Membrane-type 1 matrix metalloproteinase (MT1-MMP)
proteolytic processing is decreased in aortic aneurysms.
Homogenates of healthy aorta (n = 4) and abdominal aortic
aneurysms (AAAs; n = 5) were resolved (25 mg protein/well) on
9% SDS-polyacrylamide electrophoresis gel as described in
Materials and Methods section. A, MT1-MMP immunoreactivity
was analyzed, and 63-kd and 55-kd proteins represent
unprocessed active forms of MT1-MMP, whereas 43-kd form is
processed inactive form. Human recombinant MT1-MMP
(rMT1-MMP) was applied on gel as standard. B, Quantification
of active (healthy aorta, 100 ± 25, versus AAA, 347 ± 23) and
inactive (healthy aorta, 100 ± 11, versus AAA, 22 ± 11) forms of
MT1-MMP was performed with densitometry and is expressed as
percent of values for healthy aorta.
*Values of less than .05 were considered significant.
NA, Healthy aorta.
A
B
A
B
MMP is synthesized as a zymogen that can be processed
to its mature, catalytically active form after the removal of
its regulatory propeptide domain.11 When Western blot
test and immunodetection analysis were performed, active
(55 kd) and presumably inactive (43 kd) MT1-MMP pro-
teolytic product forms were found in equilibrium in
healthy aorta but not in AAAs (Fig 3,A). Interestingly,
active MT1-MMP was increased in AAAs (about 3.5-fold)
when compared with healthy aorta, and the proteolytic
product at 43 kd was absent from AAA specimens (Fig
3,B). Whether this 43-kd form of MT1-MMP has any
physiologic significance in the cause of AAAs has yet to be
confirmed. However, a clear correlation can be postulated
between the lack of MT1-MMP proteolytic processing
(Fig 3,B) and the MMP-2 activation (Fig 6) states, which
supports the assumption that either an up regulation of
MT1-MMP expression or a decrease of its inactivation by
proteolysis may favor the activation of pro–MMP-2 in
AAAs.
Differential protein expression of tissue inhibitors
of matrix metalloproteinase in abdominal aortic
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aneurysms. TIMPs are able to inhibit MMPs with the for-
mation of complexes and have been shown to be impor-
tant determinants of net MMP activity during neointima
formation.31 We thus decided to investigate the molecular
interplay of TIMPs on the functional regulation of
endogenous MMPs in AAAs. Western blot test of TIMP-
Fig 4. Immunoblot analysis of expressed tissue inhibitor of
matrix metalloproteinase 1 (TIMP-1), TIMP-2, and TIMP-3 in
healthy aorta and aortic aneurysms. Homogenates of healthy
aorta (n = 4) and abdominal aortic aneurysms (AAAs; n = 5)
were resolved (25 mg protein/well) on 12.5% SDS-polyacryl-
amide electrophoresis gel as described in Materials and Methods
section. A, Expression of TIMP-1, TIMP-2, and TIMP-3 was
examined. B, Quantifications of TIMP-1 (healthy aorta [NA],
100 ± 8, versus AAA, 219 ± 9), TIMP-2 (NA, 100 ± 10, versus
AAA, 14 ± 6), and TIMP-3 (NA, 100 ± 38, versus AAA, 385 ±
38) levels were performed with densitometry and are expressed as
percent of values for healthy aorta.
*Values of less than .05 were considered significant.
A
Fig 5. Matrix metalloproteinase 12 (MMP-12) protein expres-
sion and activity are increased in aortic aneurysms. A, MMP-12
expression was studied in healthy aorta (n = 3) and abdominal
aortic aneurysms (AAAs; n = 5). Artery homogenates were
resolved (25 µg protein/well) on 7.5% SDS-polyacrylamide elec-
trophoresis gel, and MMP-12 immunoreactive forms were
detected as described in Materials and Methods section. B,
MMP-12 activity in artery homogenates was analyzed with casein
zymography as described in Materials and Methods section. The
54-kd pro-MMP, 45-kd intermediate MMP-12 (iMMP-12), and
22-kd active forms of MMP-12 are identified. Standard used
(Stds) was commercially available recombinant MMP-12.
Fig 6. Matrix metalloproteinase 2 (MMP-2) and MMP-9 gelati-
nolytic activities in healthy aorta and abdominal aortic aneurysms
(AAAs). Homogenates of healthy aorta (n = 4) and AAAs (n = 5)
were submitted (25 mg protein/well) to gelatin zymography as
described in Materials and Methods section. Enzymatically active
proteins were identified with clear bands against dark background
of intact substrate. Positions of pro-MMP and active forms of
MMP-2 and pro–MMP-9 are shown and indicate main gelati-
nolytic activities. Standards used (Stds; MMP-2 and MMP-9)
were cultured medium from HT-1080 human fibrosarcoma cells.
A
B
B
1, TIMP-2, and TIMP-3 expression was performed on
homogenates of healthy arteries and AAAs. Interestingly,
protein levels were significantly up regulated for TIMP-1
(approximately 2-fold) and TIMP-3 (approximately 4-
fold), whereas the TIMP-2 protein levels were decreased
by approximately 60% (Fig 4,B). Although the homoge-
nization/extraction procedure was performed uniformly
for all our samples, the possibility that altered matrix
remodeling occurring in AAA could modulate the associ-
ation of TIMP-3 to the matrix has also to be considered.
Individually regulated TIMP expression in AAAs may thus
play specific roles in the modulation of MMP proteolytic
activities within the elastin-injured aorta.
DISCUSSION
In this report, the levels of α-actin and β-actin, two
highly conserved proteins and major components of both
the cytoskeletal and contractile structures in healthy aorta
and aortic aneurysms, were examined as markers of struc-
tural deterioration. The markedly decreased levels of α-
actin (more than 90%) reflected the severe reduction in
SMC content of our AAA specimens. This decrease may
originate either from reduced expression of SMC express-
ing a contractile phenotype32 or, alternatively, from
proapoptotic mediators associated with macrophages and
T lymphocyte infiltration at AAA sites.33 We also exam-
ined the MMPs involved in collagen and elastin degrada-
tion and found that MMP-1 and MMP-9 were
respectively up regulated either at the zymogen level or in
their functional enzymatic state, possibly in response to
cytokines (eg, tumor necrosis factor-α and interleukin-
1β)34 or macrophage infiltration.35 With immunohisto-
chemistry, MMP-1, MMP-3, MMP-9, and urinary type
plasminogen activator were indeed also reported by others
to be localized in macrophage-like mononuclear cells infil-
trating the aneurysmal aorta.25 More importantly, we pro-
vide enzymatic evidence on the functional state of
MMP-12, the macrophage metalloelastase, at the site of
aneurysmal lesions. These data support the hypothesis that
the aortic wall is being degraded in AAAs by a synergistic
combination of macrophages and MMPs. This is also in
agreement with previous studies that used in situ
hybridization and immunohistochemical approaches to
conclude that coordinate expression of MMP-1, MMP-9,
and MMP-12 in atherosclerotic lesions was responsible for
the elastin degradation.36,37
An intriguing observation is the particular regulation
of MMP-2 in our AAA specimens. The level of active
MMP-2 in aneurysms was similar to that in healthy aorta,
and the pro–MMP-2 form declined significantly. It is gen-
erally considered that pro–MMP-2 is processed and acti-
vated by membrane-type MMPs in vivo29 and that the
extent of pro–MMP-2 activation is strongly correlated
with the appearance of the 43-kd inactive MT1-MMP
form.11 Intriguingly, we show in this study that MT1-
MMP is found primarily in its active 55-kd form in AAAs.
It thus appears as if the processing of MT1-MMP to its
inactive 43-kd form is altered in AAAs. Pro–MMP-2 acti-
vation may thus be regulated through alternative mecha-
nisms. Such regulation could be achieved in AAA lesions
through a cascade of actions of other MMPs. For instance,
increased MMP-1 and MMP-12 protein expression and
activity, which can also activate pro–MMP-2,38,39 could be
considered as alternative pathways involved in pro–MMP-
2 activation in AAAs. Although the mechanisms of MT1-
MMP proteolytic processing are still debated, the
established mechanism is that it involves its cell surface
proteolysis through an adjacent activated MT1-MMP.
This process was recently investigated by our team11 and
by others.40 The MT1-MMP 43-kd form was amino acid
sequenced and found to be cleaved within its catalytic
domain. Thus, the MT1-MMP antibody used in this study
could still recognize the hinge region that is preserved
through that proteolytic processing. Moreover, MT1-
MMP proteolysis from active to inactive forms in AAAs
has not been thoroughly investigated. Although exten-
sively documented in cell cultures by our team,11,41 the
data presented in our study are, to our knowledge, the first
evidence for such immunoreactive patterns in tissue
homogenates.
Just as we have shown that MMP-1, MMP-2, and
MMP-12 seem to work in tandem to hasten vessel break-
down in AAAs, we also observed a concomitant up regula-
tion in TIMP-1 and TIMP-3 protein expression in the
aneurysm wall. Interestingly, in vitro study results have
established the human macrophages as a novel source of
TIMP-3 mRNA and protein and have established that
platelet-derived growth factor and transforming growth 
factor–β secretion by macrophages augmented levels of
TIMP-1 and TIMP-3 but not TIMP-2 in human saphe-
nous vein and arterial SMCs.42 Alternatively, because the
regulation of TIMP expression is an important determi-
nant of net MMP activity, this TIMP up regulation in
AAAs may simply represent a physiologic attempt to coun-
teract the pathologic increase in MMPs that is observed
within these tissues. This phenomenon has also been
reported in other pathologies, such as cerebral
aneurysms43 and human atheroma.42 In contrast, TIMP-2,
which is shown to be down regulated in our AAA speci-
mens, is known to bind selectively to pro–MMP-2, an
interaction that can serve to present the zymogen for acti-
vation by MT1-MMP.44 Alternatively, the binding of
TIMP-2 to active MT1-MMP was recently shown to reg-
ulate MT1-MMP proteolytic processing.40 That report
showed that TIMP-2 regulated the amount of active MT1-
MMP on the cell surface, whereas, in the absence of
TIMP-2, MT1-MMP underwent autocatalysis. The func-
tional consequences of the decrease in TIMP-2 and
increase in TIMP-3 expressions in our AAA specimens may
thus provide an explanation for the MT1-MMP that
remained trapped into its unprocessed and activated form.
TIMP-3, unlike TIMP-1, is an effective inhibitor of MT1-
MMPs. Binding to MT1-MMP may thus prevent both
autocatalysis and pro–MMP-2 activation. However, with
these pathologic conditions, the significance and function
of this MT1-MMP form remain to be established.
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Although different TIMPs bind tightly to most
MMPs, it is important to keep in mind that some differ-
ences in inhibitory properties between TIMPs exist and,
most importantly, that additional functions have been
attributed to these TIMPs, including cell growth promo-
tion and induction of apoptosis.45 In particular, TIMP-3,
which was increased in our AAA specimens and which
exhibited some matrix-binding ability,46 increased the
production of p53, mediated apoptosis in a variety of cells
including SMCs,33,47 and inhibited vascular neointima
formation in vitro and in vivo.13 TIMP-3 was also shown
to interact with both MMP-2 and MMP-9 and may thus
compensate for a decrease in TIMP-2 in AAAs.48 Finally,
TIMPs differ in the types of noninhibitory complexes that
they form with pro-MMPs and that is mediated by their
C-terminal domains. The biologic implications of this,
however, are not clear.45 Understanding the molecular
mechanisms by which TIMPs regulate functional MMPs
in AAA formation deserves further investigation and
should provide important insights into their role in matrix
homeostasis and AAA remodeling.
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